Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its third fiscal quarter of fiscal year 2013, the period ended May 31, 2013 (3QFY13).
Ms. Momoko Beran, chief financial officer of Simulations Plus, stated, “In accordance with our policy to release timely financial information to our shareholders, we are releasing preliminary revenues for 3QFY13. Net income will not be known until income taxes have been determined and our auditors review our Quarterly Report on Form 10-Q. We expect to file our 10-Q with the U.S. Securities and Exchange Commission on or before the July 15, 2013 deadline.”
Preliminary results for the quarter:
- This was the Company’s 23rd consecutive profitable quarter, and the 45th of the last 47 quarters
- Preliminary revenues increased to $3.095 million, compared to $2.772 million in 3QFY12
- This represents an increase of 11.7% over 3QFY12 and is a new record third quarter
- Approximately 11% of revenues came from new software licenses
- Approximately 7.5% of revenues came from consulting studies and collaborations
- Renewals remained strong at approximately 95%
- Cash as of May 31, 2013 was $9.9 million
Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “The third quarter of fiscal year 2013 produced yet another record quarter, with double-digit growth in revenues according to our preliminary numbers. New software licenses increased again, due in part to our successful molecule design project for malaria last year, and our funded consulting contracts and collaborations have progressed smoothly. We remain financially very strong, with our cash at just under $10 million after paying out over $5.9 million in dividends in the past 16 months, and $1.7 million in federal and state taxes, and we continue to have no debt.”